Weekly Analysts’ Ratings Updates for Theravance Biopharma (TBPH)

A number of firms have modified their ratings and price targets on shares of Theravance Biopharma (NASDAQ: TBPH) recently:

• 4/14/2026 – Theravance Biopharma was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 4/10/2026 – Theravance Biopharma was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 4/7/2026 – Theravance Biopharma had its price target raised by B. Riley Financial, Inc. from $14.00 to $17.00. They now have a “neutral” rating on the stock.
• 4/6/2026 – Theravance Biopharma was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 3/29/2026 – Theravance Biopharma was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 3/24/2026 – Theravance Biopharma was upgraded by Weiss Ratings from “hold (c)” to “buy (b-)”.
• 3/23/2026 – Theravance Biopharma had its price target raised by TD Cowen from $13.00 to $15.00. They now have a “hold” rating on the stock.
• 3/21/2026 – Theravance Biopharma was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/20/2026 – Theravance Biopharma had its “buy” rating reaffirmed by BTIG Research. They now have a $21.00 price target on the stock.
• 3/19/2026 – Theravance Biopharma was upgraded by Zacks Research from “hold” to “strong-buy”.
• 3/5/2026 – Theravance Biopharma was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”.
• 3/4/2026 – Theravance Biopharma had its “neutral” rating reaffirmed by B. Riley Financial, Inc.. They now have a $14.00 price target on the stock, down from $28.00.
• 3/3/2026 – Theravance Biopharma had its price target lowered by BTIG Research from $40.00 to $21.00. They now have a “buy” rating on the stock.
• 3/2/2026 – Theravance Biopharma had its price target raised by HC Wainwright from $20.00 to $27.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares of the company’s stock, valued at $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is currently owned by company insiders.

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.